EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Jiangxi Rimag Group Co Ltd (2522) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Jiangxi Rimag Group Co Ltd HK$2.60, price HK$5.02, upside -48.2%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · HK

JR Thin data Sep 24, 2026

Jiangxi Rimag Group Co Ltd

2522 · HK

Weakest SetupStrongly overvalued and low quality.

!Fair value HK$2.60 · Strongly overvalued (−48.2%)
!Quality 43/100
!Mixed Growth (revenue 3y +3.6 %/yr)
!Thin margins · 0.4% net margin (TTM)
✓Low debt · generates free cash flow
!Trails peers (4/13)
!Narrow moat 20/100
!Evidence only low, so the estimate is less certain
Watch Jiangxi Rimag Group Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$70.80 HK$4.45 Fair Value HK$2.60 Jun 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

28‑month range HK$4.45 – HK$70.80 · fair‑value band HK$2.49 – HK$2.69 · the HK$5.02 price screens above the HK$2.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Jiangxi Rimag Group Co in your weekly email

Every Wednesday you see whether Jiangxi Rimag Group Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Jiangxi Rimag Group Co., Ltd., together with its subsidiaries, invests in and operates medical imaging centers in Mainland China, Hong Kong, Macau, and internationally. It operates through Imaging Center Services, Imaging Solution Services, and Digital-Intelligent Services segments.

Show more

Jiangxi Rimag Group Co., Ltd., together with its subsidiaries, invests in and operates medical imaging centers in Mainland China, Hong Kong, Macau, and internationally. It operates through Imaging Center Services, Imaging Solution Services, and Digital-Intelligent Services segments. The company offers imaging examination and diagnostic imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures to hospitals and other medical institutions, health management companies, individual patients, and other healthcare customers; medical imaging operational management services; imaging equipment and software solutions; imaging capability improvement services; imaging empowerment solutions, such as equipment selection and configuration, quality control, remote consultation, medical staff training, clinical imaging capability analysis, and repair services. It also provides Rimag Cloud services, including cloud storage and cloud film modules, remote diagnosis and consultation for complex cases, remote hosting services, imaging AI integration platform, refined operation management modules, cloud radiology information system (RIS) modules, and quality control modules; data processing and analysis solutions; and remote and AI diagnosis services. In addition, the company engages in the operation and management of a medical imaging cloud platform that provides diversified imaging services; operation of a research and development center; technical support; sale of medical devices and consumables; clinic services; maintenance and installation of medical equipment; technology development of medical imaging cloud platforms; and medical imaging industry chain services. Jiangxi Rimag Group Co., Ltd. was incorporated in 2014 and is headquartered in Beijing, China.

Stock analysis

Jiangxi Rimag Group Co Ltd (2522) currently trades at HK$5.02, while our model-based Fair Value estimate is HK$2.60, implying the stock looks roughly 92.9% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of HK$3.76 per share, and 4 of the 24 models we run sit above the HK$5.02 price.

Bear case: the Economic Profit group reads lowest at HK$2.29, and 20 of the 24 models stay below the price. Evidence for this calculation is low.

Scenario range: HK$2.49 (bear) to HK$2.69 (bull), the price of HK$5.02 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Jiangxi Rimag Group Co Ltd reported revenue of 873M CNY in FY2025 versus 592M CNY in FY2021, a compound +10.2%/yr. Reported net income was 3.7M CNY in FY2025.

Key figures

Market cap HK$1.8B (≈ $229M) · P/E ratio 462.0 · P/S ratio 1.98 · EPS (TTM) HK$0.0500 · Net margin 0.4% · Return on equity −0.6% · Return on assets (EBIT) −1.6% · Operating margin −4.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 72% below its 52-week high and 13% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 21% fair-value upside, at −48%, 2522 screens richer than that median.

Fair Value models

Bear HK$2.49 Fair Value HK$2.60 Bull HK$2.69
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$0.0370 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF HK$3.35 HK$4.35 HK$5.70 77
Growth DCF HK$3.33 HK$4.23 HK$5.37 75
Owner Earnings HK$3.98 HK$5.28 HK$7.05 74
All 24 models by family
DCF Models
FCF DCF HK$3.35 HK$4.35 HK$5.70 77
Owner Earnings HK$3.98 HK$5.28 HK$7.05 74
5Y Revenue Exit HK$2.87 HK$3.68 HK$4.70 70
5Y EBITDA Exit HK$5.94 HK$9.72 HK$14.33 70
5Y P/E Exit HK$2.26 HK$2.47 HK$2.68 68
10Y Revenue Exit HK$3.02 HK$3.76 HK$4.77 64
10Y EBITDA Exit HK$4.76 HK$7.45 HK$11.35 64
10Y P/E Exit HK$2.71 HK$3.03 HK$3.39 62
Earnings-Based
Graham-Dodd HK$0.0700 HK$0.2800 HK$0.3800 59
Lynch FV HK$0.0700 HK$0.1000 HK$0.1300 56
PEG = 1.0 HK$0.0700 HK$0.1000 HK$0.1300 52
EPV HK$2.18 HK$2.29 HK$2.37 72
Multiples
P/E Multiple HK$0.1700 HK$0.2300 HK$0.2900 61
P/S Multiple HK$0.1300 HK$0.1800 HK$0.2200 56
P/B Multiple HK$0.1300 HK$0.1800 HK$0.2200 53
EV/EBIT HK$3.09 HK$3.68 HK$4.27 65
EV/EBITDA HK$8.61 HK$11.04 HK$13.48 66
EV/Revenue HK$2.58 HK$3.12 HK$3.66 53
Asset-Based
NCAV (Graham) HK$2.78 HK$3.73 HK$5.56 52
Growth DCF
Growth DCF HK$3.33 HK$4.23 HK$5.37 75
Rev-Margin DCF HK$2.87 HK$3.69 HK$4.70 70
Economic Profit
Residual Income HK$3.33 HK$2.90 HK$2.65 66
ROIC Compounder HK$2.18 HK$2.29 HK$2.37 68
Growth Earnings
Growth-Adj P/E HK$0.1300 HK$0.1800 HK$0.2300 63

Open the full fair value analysis →

Notify me when 2522 reaches fair value

Put 2522 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 46 · Market factors (momentum, volatility) 30

Profitability 16
Margins and returns on capital today
Quality Growth 56
Are margins and returns improving?
Cashflow 53
Earnings quality: real cash, not paper profit
Fin. Strength 63
Balance sheet, leverage, solvency risk
Investment 30
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 2
Distance to the 52-week high (market factor)
Net Issuance 59
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 60/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−5.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.4%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−50% → 6%

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+18.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in CNY, China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +16.7% a year for the price.

2522 screens 93% overvalued. Compare with HCA Healthcare, Inc →

Compare Jiangxi Rimag Group Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 256 stocks

Beats the industry median on 4/12 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Bottom 25%
Fair Value upside −48.2% · Bottom 25%
Profitability
Return on assets 0.5% · Bottom 25%
Net margin (TTM) 0.4% · Bottom 25%
Operating margin (TTM) −4.3% · Bottom 25%
Growth and dividend
Revenue growth 17.1% · Top 25%
Balance sheet
Debt / equity 0.08× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 462.0× · Priciest 25%
P/B 0.77× · Cheaper than median
P/S (TTM) 1.76× · Pricier than median
P/FCF 4.0× · Pricier than median
EV/EBITDA 5.7× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 33
FUTURE (revenue growth)86 · sector 28
PAST (return on equity)0 · sector 31
HEALTH (low debt)96 · sector 89
DIVIDEND (yield)0 · sector 41

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $435.61 $597.97 +37%
Fresenius SE FRE €46.15 €34.49 −25%
Dr. Sulaiman Al Habib Medical Services Group 4013 225.00 SAR 109.45 SAR −51%
Tenet Healthcare Corporation THC $259.71 $274.35 +6%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,889 ₹2,908 −67%
Encompass Health Corporation EHC $123.47 $94.47 −23%
Fresenius Medical Care AG FMS $22.69 $46.11 +103%
DaVita Inc DVA $178.47 $215.81 +21%
Aier Eye Hospital Group 300015 ¥7.91 ¥10.86 +37%
Universal Health Services, Inc UHS $178.86 $444.19 +148%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Jiangxi Rimag Group Co Ltd · Fair Value
HK$2.60 −93%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Jiangxi Rimag Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2522

Frequently asked questions

Is Jiangxi Rimag Group Co Ltd (2522) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of HK$2.60 versus a price of HK$5.02, about −48% upside (overvalued).
What is the fair value of 2522?
Our model-based fair value for Jiangxi Rimag Group Co Ltd is HK$2.60 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$5.02.
What is the quality score of 2522?
Jiangxi Rimag Group Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jiangxi Rimag Group Co Ltd (2522)?
Our model-based price target is the fair value of HK$2.60 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario HK$2.49, optimistic scenario HK$2.69. It is a calculation from audited fundamentals, not an analyst target.
What is the Jiangxi Rimag Group Co Ltd stock forecast for 2026?
Our models put fair value at HK$2.60, about −48% upside versus a price of HK$5.02 (overvalued). Cautious scenario HK$2.49, optimistic scenario HK$2.69. The calculation is refreshed regularly with new filings.
What is the revenue of Jiangxi Rimag Group Co Ltd (2522)?
Jiangxi Rimag Group Co Ltd reported trailing-twelve-month revenue of about 873M CNY (latest available figure, as of Sep 24, 2026).
What growth is priced into Jiangxi Rimag Group Co Ltd (2522)?
For today's price to be fair in a discounted-cash-flow model, Jiangxi Rimag Group Co Ltd would have to grow free cash flow by +18.7 % per year for five years (discount rate 13.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +10.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 2522 use?
Our models discount Jiangxi Rimag Group Co Ltd at 13.3 %: a base by market capitalisation (micro), country premium for Hong Kong. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jiangxi Rimag Group Co Ltd that is +18.7 % per year a year over ten years, using the same discount rate (13.3 %) and the same formula as our fair value.
How much growth has Jiangxi Rimag Group Co Ltd (2522) delivered so far?
Over the past 4 years revenue at Jiangxi Rimag Group Co Ltd grew +10.2 % a year. The price currently implies +18.7 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jiangxi Rimag Group Co Ltd (2522) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Jiangxi Rimag Group Co Ltd (+18.7 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jiangxi Rimag Group Co Ltd (2522)?
The free-cash-flow yield on the price is 3.76 %: that much free cash flow Jiangxi Rimag Group Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (13.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jiangxi Rimag Group Co Ltd (2522)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jiangxi Rimag Group Co Ltd it is HK$2.60 per share (as of Sep 24, 2026), against a price of HK$5.02. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Jiangxi Rimag Group Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 2522 trades above its calculated fair value: price HK$5.02, fair value HK$2.60, a gap of about −48% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2522?
No. The price is what the market pays today (HK$5.02); the fair value is what the company's own numbers justify (HK$2.60). For Jiangxi Rimag Group Co Ltd the two are HK$2.42 per share apart. That gap is exactly why we show both numbers side by side.
How much is Jiangxi Rimag Group Co Ltd worth?
The market values Jiangxi Rimag Group Co Ltd at about HK$1.8B (market capitalisation, as of Sep 24, 2026). Per share that is HK$5.02; our models calculate a fair value of HK$2.60 per share.
What do the bullish and bearish scenarios say about 2522?
Our models span a range for Jiangxi Rimag Group Co Ltd: cautious scenario HK$2.49, base HK$2.60, optimistic HK$2.69 per share (as of Sep 24, 2026, price HK$5.02). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2522?
Jiangxi Rimag Group Co Ltd trades at a price-to-earnings ratio of 462.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$2.60 is built from several models across several years. Other multiples: P/B 0.8, P/S 1.8, EV/EBITDA 5.7.
How solid is the balance sheet of Jiangxi Rimag Group Co Ltd (2522)?
Balance-sheet figures for Jiangxi Rimag Group Co Ltd (as of Sep 24, 2026): return on equity −0.6%, debt of 0.08 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 2522 from its 52-week high?
Jiangxi Rimag Group Co Ltd trades at HK$5.02, about 72% below its 52-week high of HK$17.83 and 13% above the low of HK$4.45 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of HK$2.60 is for.
Which stocks are comparable to Jiangxi Rimag Group Co Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jiangxi Rimag Group Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price HK$5.02, calculated fair value HK$2.60 (−48%), Quality Score 43/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2522 calculated?
We run Jiangxi Rimag Group Co Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$2.60, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9 % above its aggregate fair value. Jiangxi Rimag Group Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jiangxi Rimag Group Co Ltd (2522)?
The closing price on Sep 25, 2026 was HK$5.02. Our model-based fair value is HK$2.60, about −48% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jiangxi Rimag Group Co Ltd right now?
The price sits above even our optimistic bull case (HK$2.69). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (HK$2.49 to HK$2.69), unusually little disagreement for a valuation.

Key figures of Jiangxi Rimag Group Co Ltd

How large is the market capitalisation of Jiangxi Rimag Group Co Ltd (2522)?
The market capitalisation of Jiangxi Rimag Group Co Ltd is HK$1.8B (≈ $229M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jiangxi Rimag Group Co Ltd (2522)?
The price-to-sales ratio of Jiangxi Rimag Group Co Ltd is 1.98 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jiangxi Rimag Group Co Ltd (2522)?
Earnings per share at Jiangxi Rimag Group Co Ltd are HK$0.0500 (price ÷ EPS = P/E 462.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Jiangxi Rimag Group Co Ltd (2522)?
The net margin of Jiangxi Rimag Group Co Ltd is 0.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jiangxi Rimag Group Co Ltd (2522)?
The return on equity (ROE) of Jiangxi Rimag Group Co Ltd is −0.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jiangxi Rimag Group Co Ltd (2522)?
On an EBIT basis the return on assets of Jiangxi Rimag Group Co Ltd is −1.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jiangxi Rimag Group Co Ltd (2522)?
The operating margin of Jiangxi Rimag Group Co Ltd is −4.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jiangxi Rimag Group Co Ltd (2522)?
Revenue at Jiangxi Rimag Group Co Ltd is growing +17.1% versus a year earlier (3y avg +3.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jiangxi Rimag Group Co Ltd (2522)?
Earnings per share at Jiangxi Rimag Group Co Ltd are growing +318% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Jiangxi Rimag Group Co Ltd (2522) hold?
Jiangxi Rimag Group Co Ltd holds more cash than debt, 1.3M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Jiangxi Rimag Group Co Ltd in the live analysis

One click puts Jiangxi Rimag Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.